
Medical workers should have anti-HBV antibody to protect HBV infection in the hospital. If they have not anti-HBV antibody, they should receive HBV vaccination. HBV vaccination program is as follows: 10 micrograms, s.c., 0, 1, 6 months. In case of HBV contamination, 1,000 IU hepatitis B immune globulin(HBIG) and/or 10 micrograms HB vaccine should be administered judging from HBV markers of contaminated subjects and HBV load of patients. The HCV vaccine is not available. In case of HCV contamination, it is unnecessary to treat just after accident. If acute hepatitis C is evolved in those subjects during follow-up, it is recommended to treat with interferon. Eradication of HCV by interferon among patients with acute hepatitis C will be almost 100%.
Cross Infection, Infection Control, Infectious Disease Transmission, Patient-to-Professional, Immunoglobulins, Hepatitis B, Hepatitis C, Accidents, Occupational, Humans, Hepatitis B Vaccines, Interferons, Needlestick Injuries
Cross Infection, Infection Control, Infectious Disease Transmission, Patient-to-Professional, Immunoglobulins, Hepatitis B, Hepatitis C, Accidents, Occupational, Humans, Hepatitis B Vaccines, Interferons, Needlestick Injuries
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
